Thomas Lingelbach
President, CEO & DirectorMr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and served as its Chairman and Member of the Management Board since May 10, 2013 until December 20, 2023 and serves as Director since December 20, 2023. Mr. Lingelbach serves as a Managing Director of Valneva Scotland Ltd. Mr. Lingelbach had been Co-President of Valneva SE since July 17, 2017 and serves as its President since May 2013. He served as Chairman of the Management Board of Intercell Ag and served as its Chief Executive Officer since May 10, 2011. He served as the Managing Director of Intercell Ag. since August 3, 2006 until 2013. He serves as the President of Valneva USA, Inc. since 2008. He has a long international pharmaceutical management track-record and extensive knowledge and expertise in the field of development, industrialization and commercialization of vaccines. He served as the Chief Executive Officer of Valneva USA, Inc. He joined Intercell in 2006. He served as the Chief Operating Officer of Intercell Biomedical Research & Development AG (Intercell) since August 3, 2006 and served as its Member of the Management Board since November 2007. He has experience in the phar-ma and vaccines industry, having held a variety of leading positions of increasing international responsibility at Hoechst AG from 1989 to 1993, Behringwerke AG (1993-1997), Chiron Vaccines (1997-2005) and Novartis Vaccines and Diagnostics (2005-2006), Mr. Lingelbach has been significantly involved in Novartis' Vaccines and Diagnostics integration activities acting as General Manager and Managing Director of its German Vaccines Operations. Since 2001 until Chiron's acquisition by Novartis in April 2006, he served as a Vice President Industrial Operations in Chiron Vaccines' Executive Committee from 2003 to 2006 and as well as Managing Director of Chiron-Behring GmbH & Co. KG in Germany from 2001 to 2006. He serves as President of the CMC Board of Hookipa Pharma Incorporated. He has been a Director of Valneva USA, Inc. since 2008. Mr. Lingelbach holds a Master's Degree in Engineering and complemented his Education with a Business Administration program from 1999 to 2000 with a Business Administration program. Mr. Lingelbach holds an M.S. in Engineering, specialised in bioprocess engineering, from Technische Hochschule Mittelhessen (THM).
Positions
- Company NameValneva SEStock CodeVALNPositionPresident, CEO & DirectorColleagues
- GZGerd ZettlmeisslIndependent Chair of the Board
- PBPeter BuhlerChief Financial Officer
- JJJuan-Carlos JaramilloChief Medical Officer
- DPDipal PatelChief Commercial Officer
- VDVincent DequenneChief Operating Officer
- JRJames R. SulatIndependent Vice Chairman
- AGAnne-Marie GraffinVice-Chair of the Board
- RLRalf Leo ClemensChair of Scientific Advisory Board
